Skip to Content

Pegvisomant Dosage

Medically reviewed on February 4, 2019.

Applies to the following strengths: 10 mg; 15 mg; 20 mg; 25 mg; 30 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Acromegaly

Initial dose: 40 mg by subcutaneous injection.
Maintenance dose: 10 to 30 mg by subcutaneous injection daily.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Patients with elevated liver test (LT) results (alanine aminotransferase, aspartate aminotransferase, total bilirubin and alkaline phosphatase) less than or equal to 3 times the upper limit of normal may be treated with pegvisomant with monthly LT monitoring. Patients with LT results greater than 3 times the upper limit of normal should not be treated with pegvisomant until a comprehensive workup establishes the cause of the patient's liver dysfunction.

Dose Adjustments

The dosage is adjusted in 5 mg increments every 4 to 6 weeks based on serum concentrations of insulin like growth factor I (IGF I). The goal of therapy is to achieve and maintain normal serum IGF I levels.


Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.